9月19日，苏州丨VenrockChinaDayForum，KenSong携Venrock投资团队现身

引言

Venrock 成立于1969 年，最初为 Rockefeller 家族旗下的风险投资机构，至今已拥有超过半个世纪的投资历史。作为全球领先的风险投资机构之一，Venrock 长期专注于Healthcare 与 Technology，持续与优秀创业者合作，投资并推动了一批具有全球影响力的创新企业，包括Apple, Intel, Cloudflare, Gilead, Biogen, Illumina, Centocor, athenahealth, Shockwave Medical, Avexis, Apogee, and RayzeBio等。

2026年9月19日，中国苏州，将召开Venrock China Day Forum，Venrock全球投资团队将来到中国，分享Venrock的投资重点与中国策略，并将于与中国 Biotech 创始人、投资人及产业创新者深入交流，共同探索中国创新与全球资本的连接与合作。

其中，Ken Song现任 Venrock Partner，曾担任Candid Therapeutics 联合创始人、总裁兼 CEO。Candid 从 2024 年创立到 2026 年被 UCB 以最高22亿美元收购，是近年来全球 Biotech 领域极具代表性的创业与并购案例。

会上，Ken Song 也将携手Cindy Xiong、Derek Yuan、Kan Chen、Chengbin Wu等首次在中国分享，Candid 从创立到被收购的完整历程与关键决策，敬请期待。

以下是会议日程。Enjoy！

Venrock China Day Forum 2026

Organized by Venrock, BioBAY & BioPlus Partners

Venue: Jinji Lake Roadshow Center, 1F, Block A1, No. 218 Xinghu Street, Suzhou, China

Date: Sat, Sep 19, 2026

Audience: Exclusively for invited and vetted executives -100 selected attendees

Language: English

Scan to Register & Apply for 1-on-1 (Deck Submission: For a better upload experience, we recommend using a PC.)

Or visit the registration page on PC: https://event.mymova.com/spa2/#/?eventname=bioplusvcdf&ticket=73432

Why Attend?

• Meet Venrock Team

Meet Venrock’s investment team and gain insights into its investment focus and China strategy.

• Uncover the Candid Story — Firsthand

For the first time in China, hear directly from Candid’s founding team about the journey from founding to UCB’s acquisition—including the deal story and key lessons along the way.

• Explore China’s Biotech Ecosystem

Discover China’s biotech innovation ecosystem and connect with leading investors, biotech founders, executives, and industry leaders through high-level networking.

Agenda

Morning Session (8:30 AM- 12:30 PM)

1-on-1 Meetings with Venrock Team (by invitation only)

Venue: Crick Conference Room and Darwin Conference Room

• 20 meetings in total

• 20 minutes per meeting

• Companies will submit non-confidential decks in advance for Venrock’s review and selection

What We’re Looking For ?

• Disease Area & Modality: Broad interest

• Program Stage: PCC to Phase 3

• How We Would Like to Partner: Direct investment, NewCo / licensing, or other flexible partnering structures

Afternoon Session (2:00 PM-5:30 PM)

Venrock China Day Forum 2026

2:00-2:30 Check in and welcome coffee

Session Chair:

Cindy Xiong: Partner, Venrock

2:30- 2:40Welcome Remarks

• Ken Song: Partner, Venrock

• Jianguo Yin: Chairman, BioBAY

• Yuan Li: CEO, BioPlus Partners

2:40-3:00 Keynote: How I see China innovation?

Ken Song: Partner, Venrock

3:00-3:40 Fireside Chat: Venrock investment focus & China strategy

Panelists:

• Ken Song: Partner, Venrock

• Cindy Xiong: Partner, Venrock

• Derek Yuan: Partner, Venrock

• Kevin Tyan: Investor, Venrock

Moderator:

• Chengbin Wu: Founder and CEO, EpimAb

3:40-4:00 Tea Break & Networking

4:00 -4:45Panel 1: The story behind Candid-from founding to UCB acquisition: lessons from the journey

Panelists:

• Ken Song: Partner, Venrock; Former President and CEO, Candid Therapeutics

• Derek Yuan: Partner, Venrock; Former China General Manager, Candid Therapeutics

• Kan Chen: Co-head of Healthcare, Qiming Ventures

• Chengbin Wu: Founder and CEO, EpimAb

Moderator:

• Cindy Xiong: Partner, Venrock; Former Partner, Foresite Capital

4:45 - 5:30 Panel 2: Taking China'sinnovation global: Howcan global funds best partner with the local ecosystem?

Paneslits:

• Cindy Xiong: Partner, Venrock

• Jieyu Zou: Partner, Lilly Asia Ventures

• Shujun Yang: Executive Director, Legend Capital

• Zhaomin Chen: Principal, Hillhouse Investment (Moderator)

5:30 -7:30 PM

Wine & Dinner Reception

Networking reception with invited guests, speakers, investors, and biotech executives.

About Venrock

Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock partners with entrepreneurs to build some of the world’s most disruptive, successful companies. With a primary focus on technology and healthcare, portfolio companies have included Apple, Intel, Cloudflare, Gilead, Biogen, Illumina, Centocor, athenahealth, Shockwave Medical, Avexis, Apogee, and RayzeBio.For more information, please visit Venrock’s website at www.venrock.com.

About BioBAY

BioBAY, Which opened in June 2007, is a professional science and technology innovation carrier built by Suzhou Industrial Park (SIP) for the development of biomedical industry. Over the past 20 years, it has built facilities with a total floor area of 2.32 million square meters which are home to more than 630 innovative biomedicine enterprises. An industrial cluster focusing on innovative drugs, medical devices and in-vitro diagnostics as well as biotechnology has taken shape. BioBAY will continue to provide new physical spaces, new public service platforms and new industrial ecosystems for enterprises to develop cutting edge technologies, such as those for cell and gene therapies, RNA Therapy, Al in drug discovery, medical robots, IVD, cardiovascular interventional medical devices. BioBAY hopes to make more contributions to the development of the biomedical industry in SIP and the health of all human beings.

About BioPlus Partners

Based in Shanghai and Suzhou, BioPlus Partners is a specialized healthcare consulting firm connecting global biotech and investment communities with China’s dynamic life sciences ecosystem.With a network of 600+ partners across China and globally, spanning biopharma, venture capital, hospitals, CRO/CDMOs, and academia, we provide strategic support across innovation scouting, clinical development (particularly IITs and Phase I trials), cross-border business development, investment opportunities, and strategic events.

Meeting Inquiries

Lisa Li @BioPlus

Tel & Wechat: 86 18662346610

Email: lisa.li@bp-bioplus.com